CD+8 cells from HIV-infected individuals can control virus replication in CD4+ lymphocytes and macrophages by a noncytotoxic mechanism. We and others have determined that this non-MHC restricted antiviral response is mediated at least in part by a novel antiviral factor (CAF) produced by CD8+ cells. CAF is made at highest levels by CD8+ cells from asymptomatic individuals and long-term survivors. Its production decreases with progression to disease. Previous studies indicate that CAF is heat- and low pH-stable, has a size of 30 kD or less, and is a protein resistant to trypsin and sensitive to staph V8 protease. We I- lave since determined that CAF can be produced by cells grown in serum- free medium and the protein appears glycosylated based on its recovery from ConA columns. In comprehensive studies, we have shown that CAF lacks identity to other known cytokines including the beta-chemokines. We have also demonstrated that lL2 and antibodies to CD28 can increase the CD8+ cell antiviral response. Toward recovery and identification of CAF, we have established Herpes virus saimiri-transformed CD8+ cells producing this factor as well as T cell hybridoma lines releasing CAF. The major objective of the present proposal is to purify CAF so that its amino acid sequence can be determined and subsequent cloning and expression of the factor can be undertaken. The approaches include standard protein purification methods (i.e., column chromatography, isoelectric focusing, and gel electrophoresis) using an algorithm that removes albumin from the serum-free medium and permits concentration of the factor. Monoclonal antibodies to CAF will be produced to help in purification. With these antibodies, an ELISA assay will be developed to assess the presence of the factor in blood and body fluids, and to evaluate methods for enhancing its production in the host. The antibody can also be useful to detect and quantitate CAF-producing cells by flow cytometry.A molecular approach to identify CAF is also proposed in which representational difference analysis(RDA) will be utilized using either CAF-producing and non-producing cell clones or CD8+ cells from an individual before and after production of CAF. These molecular studies could lead to the detection of CAF-specific mRNA. Subsequent cloning of the gene and expression in mammalian cells would be undertaken. The ultimate objective is to evaluate CAF as a therapeutic approach to control HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI030350-08
Application #
2672027
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1990-06-01
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Mackewicz, Carl E; Wang, Baikun; Metkar, Sunil et al. (2003) Lack of the CD8+ cell anti-HIV factor in CD8+ cell granules. Blood 102:180-3
Mackewicz, Carl E; Craik, Charles S; Levy, Jay A (2003) The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci U S A 100:3433-8
Mackewicz, Carl E; Yuan, Jun; Tran, Patti et al. (2003) alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17:F23-32
Levy, Jay A; Scott, Iain; Mackewicz, Carl (2003) Protection from HIV/AIDS: the importance of innate immunity. Clin Immunol 108:167-74
Levy, Jay A (2003) The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 24:628-32
Mackewicz, C E; Lieberman, J; Froelich, C et al. (2000) HIV virions and HIV infection in vitro are unaffected by human granzymes A and B. AIDS Res Hum Retroviruses 16:367-72
Mackewicz, C E; Patterson, B K; Lee, S A et al. (2000) CD8(+) cell noncytotoxic anti-human immunodeficiency virus response inhibits expression of viral RNA but not reverse transcription or provirus integration. J Gen Virol 81:1261-4
Mackewicz, C E; Ridha, S; Levy, J A (2000) HIV virions and HIV replication are unaffected by granulysin. AIDS 14:328-30
Greco, G; Mackewicz, C; Levy, J A (1999) Sensitivity of human immunodeficiency virus infection to various alpha, beta and gamma chemokines. J Gen Virol 80 ( Pt 9):2369-73
Mackewicz, C E; Garovoy, M R; Levy, J A (1998) HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication. J Virol 72:10165-70

Showing the most recent 10 out of 24 publications